Lonza Group Ag (OTCMKTS:LZAGY) Sees Significant Growth in Short Interest
by Danessa Lincoln · The Markets DailyLonza Group Ag (OTCMKTS:LZAGY – Get Free Report) was the target of a large growth in short interest in July. As of July 15th, there was short interest totaling 56,620 shares, a growth of 79.1% from the June 30th total of 31,620 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 88,554 shares, the days-to-cover ratio is currently 0.6 days.
Lonza Group Price Performance
LZAGY stock traded down $1.55 during midday trading on Friday, reaching $69.59. The company had a trading volume of 25,916 shares, compared to its average volume of 47,536. Lonza Group has a fifty-two week low of $58.53 and a fifty-two week high of $73.85. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.24. The stock has a 50 day moving average price of $66.28 and a 200 day moving average price of $65.65.
Wall Street Analysts Forecast Growth
Separately, Zacks Research raised Lonza Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.
Check Out Our Latest Research Report on Lonza Group
Lonza Group Company Profile
Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.
The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.